CD74-NRG1 was found to signal through induction of ERBB2-ERBB3 heterodimers. In light of the multitude of available drugs or drugs in clinical trials targeting ERBB2, ERBB3 and their downstream pathways, the detection of CD74-NRG1 fusions may aid making a decision on the appropriate medical treatment e.g. for invasive mucinous lung adenocarcinomas.
Furthermore, the fusion itself represents a promising target for the development of medical interventions.
Thus, these findings position MTSS1-NRG1 and CD74-NRG1 as druggable oncogenic fusions.
On behalf of the University of Cologne, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development.
In case of interest, we are pleased to inform you about the current status of the patent.
Fernandez-Cuesta, L. et al. (2014) CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4(4):415-22
Nakaoku, T. et al. (2014) Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 20(12):3087-93
Duruisseaux M. and Wislez M (2014) CD74-NRG1: a new fusion gene in lung adenocarcinomas characterizing mucinous adenocarcinomas. Bull Cancer 2014 Jun; 101(6):529-30
Gow, Ch. et al. (2014) Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case. Med Oncol. 2014 Jul; 31(7):34